Literature DB >> 9765474

Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver.

A Lieber1, C Y He, L Meuse, C Himeda, C Wilson, M A Kay.   

Abstract

NF-kappaB is a key regulator of the innate antiviral immune response, due in part to its transcriptional activation of cytokines and adhesion molecules, which, in turn, function in chemotaxis and activation of inflammatory cells. We reported earlier that viral gene expression in hepatocytes transduced with first-generation (E1-deleted) adenoviruses induced NF-kappaB activation, elevation of serum cytokines, and hepatocellular apoptosis during the first days postinfusion. These events did not occur in mice infused with an adenovirus vector deleted for E1, E2, E3, and late gene expression. In the present study, we used an adenovirus expressing an IkappaBalpha supersuppressor (Ad.IkappaBM) and bcl-2 transgenic mice to unravel the role of virus-induced NF-kappaB activation and apoptosis in the clearance of recombinant adenovirus vectors from the liver. The combined action of IkappaBM and Bcl-2 allowed for vector persistence in livers of C57BL/6 x C3H mice. In the absence of Bcl-2, IkappaBM expression in mouse livers significantly reduced NF-kappaB activation, cytokine expression, leukocyte infiltration, and the humoral immune response against the transgene product; however, this was not sufficient to prevent the decline of vector DNA in transduced cells. Infusion of Ad.IkappaBM caused extended apoptosis predominantly in periportal liver regions, indicating that NF-kappaB activation may protect transduced hepatocytes from apoptosis induced by adenovirus gene products. To confer vector persistence, bcl-2 transgene expression was required to block virus-induced apoptosis if NF-kappaB protection was inactivated by IkappaBM. Expression of gene products involved in early stages of apoptotic pathways was up-regulated in response to virus infusion in bcl-2 transgenic mice, which may represent a compensatory effect. Our study supports the idea that the suppression of innate defense mechanisms improves vector persistence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765474      PMCID: PMC110346     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

Review 1.  The proto-oncogene Bcl-2 and its role in regulating apoptosis.

Authors:  G Kroemer
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

2.  Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.

Authors:  N Morral; W O'Neal; H Zhou; C Langston; A Beaudet
Journal:  Hum Gene Ther       Date:  1997-07-01       Impact factor: 5.695

Review 3.  NF-kappaB activation: the I kappaB kinase revealed?

Authors:  I Stancovski; D Baltimore
Journal:  Cell       Date:  1997-10-31       Impact factor: 41.582

4.  Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues.

Authors:  Y Yang; Q Su; I S Grewal; R Schilz; R A Flavell; J M Wilson
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

5.  Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.

Authors:  A Lieber; C Y He; I Kirillova; M A Kay
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

6.  Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression.

Authors:  Y Ilan; G Droguett; N R Chowdhury; Y Li; K Sengupta; N R Thummala; A Davidson; J R Chowdhury; M S Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

7.  Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis.

Authors:  S Grimm; M K Bauer; P A Baeuerle; K Schulze-Osthoff
Journal:  J Cell Biol       Date:  1996-07       Impact factor: 10.539

8.  Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes.

Authors:  M A Kay; F Graham; F Leland; S L Woo
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

9.  Tumor necrosis factor alpha induces the adenovirus early 3 promoter by activation of NF-kappaB.

Authors:  F Deryckere; H G Burgert
Journal:  J Biol Chem       Date:  1996-11-22       Impact factor: 5.157

10.  Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2.

Authors:  S Krajewski; M Krajewska; A Shabaik; T Miyashita; H G Wang; J C Reed
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

View more
  18 in total

1.  An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency.

Authors:  B T Tan; L Wu; A J Berk
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector.

Authors:  D M Shayakhmetov; T Papayannopoulou; G Stamatoyannopoulos; A Lieber
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Shaoheng Ni; André Lieber
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

4.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

5.  Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas.

Authors:  Kyle D Weaver; Susan Yeyeodu; James C Cusack; Albert S Baldwin; Matthew G Ewend
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

6.  B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.

Authors:  Kendra M Viner; Natasha Girgis; Heesun Kwak; Stuart N Isaacs
Journal:  Virology       Date:  2006-12-26       Impact factor: 3.616

7.  Inhibition of tumor necrosis factor alpha-induced NF-kappa B activation by the adenovirus E3-10.4/14.5K complex.

Authors:  Joshua M Friedman; Marshall S Horwitz
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

8.  Adenovirus-mediated gene expression in vivo is enhanced by the antiapoptotic bcl-2 gene.

Authors:  G Bilbao; J L Contreras; H G Zhang; M J Pike; K Overturf; G Mikheeva; V Krasnykh; D T Curiel
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

9.  GammadeltaT cells initiate acute inflammation and injury in adenovirus-infected liver via cytokine-chemokine cross talk.

Authors:  Maureen N Ajuebor; Yijun Jin; Griffin L Gremillion; Robert M Strieter; Qingling Chen; Patrick A Adegboyega
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

10.  Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression.

Authors:  Daniel Stone; Weidong Xiong; Judith C Williams; Anne David; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Ther       Date:  2003-09       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.